Stockscreener 앱 받기
1.67
6.18%
-0.11
시간 외 거래:
1.67
전일 마감가:
$1.78
열려 있는:
$1.735
하루 거래량:
576.72K
Relative Volume:
0.19
시가총액:
$90.68M
수익:
-
순이익/손실:
$-82.44M
주가수익비율:
-0.8883
EPS:
-1.88
순현금흐름:
$-66.75M
1주 성능:
+4.37%
1개월 성능:
+19.29%
6개월 성능:
-48.62%
1년 성능:
-76.01%
1일 변동 폭
$1.66
$1.77
1주일 범위
$1.525
$1.79
52주 변동 폭
$1.195
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
명칭
Black Diamond Therapeutics Inc
전화
617-417-5868
주소
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
BDTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.67 | 90.68M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-31 | 개시 | Raymond James | Outperform |
| 2023-07-14 | 개시 | Piper Sandler | Overweight |
| 2023-06-30 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-03-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-03-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-01-07 | 개시 | Wedbush | Outperform |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | Canaccord Genuity | Buy |
| 2020-02-24 | 개시 | Cowen | Outperform |
| 2020-02-24 | 개시 | JP Morgan | Overweight |
| 2020-02-24 | 개시 | Jefferies | Buy |
모두보기
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Positive week for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) institutional investors who lost 74% over the past year - Yahoo Finance
A History of Outperforming Analyst Forecasts and Beating the Odds: Black Diamond Therapeutics Inc (BDTX) - Sete News
Black Diamond Therapeutics Inc (BDTX) stock analysis: A comprehensive overview - uspostnews.com
Black Diamond Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.0161: Will the Stock Break Through? - investchronicle.com
Geode Capital Management LLC Has $2.05 Million Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Financial Metrics Exploration: Understanding Black Diamond Therapeutics Inc (BDTX) Through Ratios - DWinneX
Black Diamond Therapeutics Inc (BDTX) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Head-To-Head Contrast: Avalon GloboCare (NASDAQ:ALBT) and Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Wellington Management Group LLP - Defense World
Raymond James Financial Inc. Purchases New Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Sei Investments Co. Purchases Shares of 22,802 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX Stock Sees Decline of Approximately -12.66% in Last Five Days - knoxdaily.com
Black Diamond stock hits 52-week low at $1.42 amid challenges - Investing.com India
Black Diamond stock hits 52-week low at $1.42 amid challenges By Investing.com - Investing.com South Africa
Black Diamond Therapeutics Inc [BDTX] stock for 11,997,749 USD was sold by BIOTECH GROWTH N V - knoxdaily.com
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Stock Holdings Raised by Intech Investment Management LLC - The AM Reporter
Bank of New York Mellon Corp Purchases 65,341 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics’ Global Licensing Deal with Servier - Global Legal Chronicle
BDTX stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
What is Wedbush’s Estimate for BDTX Q1 Earnings? - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 37,472 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BB Biotech AG Reduces Stake in Black Diamond Therapeutics Inc - GuruFocus
Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX - Benzinga
Stock Traders Buy High Volume of Call Options on Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Growth Stocks To Add to Your Watchlist – March 19th - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Earns “Outperform” Rating from Wedbush - Defense World
HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings - Defense World
Black Diamond Therapeutics sees $11.99m stock sale by BB Biotech AG - Investing.com
Growth Stocks To Add to Your WatchlistMarch 19th - MarketBeat
Black Diamond Therapeutics Surge: Savvy Move or Bubble? - timothysykes.com
Black Diamond Gets The Gift Of Time In License Pact With Servier - insights.citeline.com
Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com South Africa
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com
Sector Update: Health Care -March 19, 2025 at 03:43 pm EDT - Marketscreener.com
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - NewsBreak: Local News & Alerts
This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement - The Globe and Mail
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable
Black Diamond Therapeutics surges on licensing deal - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga
Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph
Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha
Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com
Black Diamond Therapeutics Inc (BDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):